It’s been eleven years since marijuana was decriminalized in Argentina. Lawmakers in the country have been reluctant in granting the industry a green signal for the longest time now. However, this year Argentina has finally gotten the ball rolling for its industry by announcing the launch of its first-ever cannabis medicine.
Argentina’s National Administration of Drugs, Foods and Medical Devices has recently authorized Laboratorio Alef Medical Argentina to launch Convuidiol. The contract is going to be valid for the next five years. During this period, Alef Medical Argentina will continue to provide high quality and international grade cannabis medicine to the market.
Argentina’s First-Ever Cannabis Medication
Convupidiol is going to embark on its journey as a debutant locally produced cannabis medicine in Argentina. Just like Epidiolex, it is going to be among the very few cannabis-infused drugs that are approved by the FDA. It is expected to reach patients by the start of next year if everything goes according to plan.
Derived from parts of the cannabis plant, each milliliter of the medication will contain around 100 mg of CBD. It will be available in the form of an oral solution and sold in 35 ml bottles. Its inactive ingredients include pharmaceutical-grade sesame oil and a vanilla flavoring for an enhanced taste.
Convupidiol will be used to treat certain types of seizures. It is considered safe for use by children as young as 2 years old. All those above this age are eligible to use the medicine upon approval from certified physicians.
Being the first of its kind type of product in Argentina, Convupidiol is setting the path straight for other similar products. If the legislation shows more flexibility, the market of cannabis and its derivatives can bring a welcoming change in the country’s economy.
Argentina’s Marijuana Laws
It takes a lot of time before legislative changes can take effect and show their impact on the economy. The launch of Convupidiol in Argentina is a classic example that reflects the scenario.
Although the medicinal usage of marijuana was legalized in the country in March of 2017, it took almost four years for the first cannabis medicine to be produced. Ideally, it would have been a great progressive step if productions of cannabis medicine were to start immediately. In contrast to this, sources have claimed that Alef Medical Argentina has yet to obtain approval for its first batch of production.
The move is expected to improve prospects within the cannabis industry but experts believe there is still a long road ahead. According to a report, the local legal cannabis market in Argentina only meets about a fraction of the demand of the population. A majority of these needs are met with imports under a special scheme that allows the ‘compassionate-use’ of medical marijuana products.
“This is a solution for cannabis companies that want to export to individual patients in countries such as Brazil or Argentina but face the logistical and economic impracticality of having to obtain at origin an export permit for each individual shipment,” says Bruno Guella, MD of MVD Free Airport.
Barriers in the industry
The progress of practical steps to relax laws in the cannabis industry has been very slow in Argentina. One of the most historic moves by the government was perhaps a unanimous approval to legalize medicinal usage of cannabis in the country. All 58 senators who were present during the voting session on cannabis legalization favored it.
Although the new laws do permit medical usage of marijuana, only limited strains are qualifiable to pass the legal barrier. Not all cannabis derivatives are permitted to be used, even medicinally. In addition, only a limited number of qualifying medical conditions make a patient eligible to receive treatment through marijuana. This has created many barriers for those outside the list of qualifying conditions to get access to treatment.
In addition to this, cultivation, resale, and production of the plant are strictly prohibited for personal recreational use. Those found committing the crime can be jailed for 15 years on top of paying fines. Only government authorized agencies can permit or process cultivation, production and resale of the drug.
However, the legislature makes a provision for importing certain products.
The costs associated with the import of products have forced many patients to depend on the illicit drug market.
Mayor To Cut the Ribbon on Cannabis ‘Cookies’ Inauguration
Michigan is seeing an increase in activities and businesses trading in marijuana. As the marijuana economy grows, Cookies is the newest store that opens its doors to Kalamazoo city. The Cookies cannabis store will be functional from Friday, Feb. 26.
The mayor for the city of Kalamazoo, David Anderson, is the chief guest for the ribbon-cutting ceremony. The store opening will be in the morning, according to the Cookies Cannabis Official press release. Also, the address for the store is 2712 Portage Street.
Medicinal Cannabis At The Curbside
The Cannabis Cookies store will not be offering curbside sales on its first day. For medicinal marijuana sales, curbside medical sales will be active from Saturday, Feb. 27, the press release further adds.
Cookies is an international cannabis lifestyle brand founded by California rapper and entrepreneur, Berner.
Cookies CEO Berner has high hopes for the Midwest. He thinks that stores like his will boost the marijuana economy and can support the economy even during slumps. Cookies has pinpointed the region as pivotal going forwards. The partnership with Gage Cannabis is also proving great for them as the demand for cannabis and medical marijuana is increasing day by day.
The expansion is driven by key partnerships and a high influx of consumers. Consumers are not only driving up demand in Kalamazoo but in the whole of Michigan. Cookies hopes to serve this rising demand as it strikes new partnerships throughout the region.
Texas Med Store Starts Selling Cannabis-Infused Gummies As Medical Marijuana
As more and more states legalize cannabis use, dispensaries are finding new ways to morph cannabis into daily-use things. The popularity of medical marijuana is undoubtedly off the charts. In another of such events, one of the state’s dispensaries now offers medical marijuana-infused gummies.
The Lone Star state is the second largest of all the states, falling behind Alaska. The fact that Elon Musk has set up his residence in the state has made it even more popular. Surterra Wellness, a well-known Florida-based marijuana company, is also operating in Texas. with a dispensary in Austin — launched its line of Surterra Wellness is bringing cannabis-infused lineup of edibles to cater to the needs of patients and cannabis consumers alike. This will provide patients with THC in a less intimidating form. The president of Surterra Wellness is positive about the impact this lineup of edibles can have.
Gummy Bears Carrying Marijuana
Mr. Ruark, the Surterra Wellness president, believes that the popularity of gummies makes them ideal to administer medicinal marijuana. Gummies are by far the most popular dosing form in medical markets across the United States. In addition to the popularity of gummies, they also contain terpenes. Terpenes provide a plethora of therapeutic properties and is an all natural extract.
They also give medical marijuana users a new way of ingesting THC. The many flavors that gummy bears are available, make it a great option to use for the deliverance of medical marijuana.
Medicinal marijuana, although legal in Texas, is under extreme regulation and restrictions. Residents must opt into the Texas Compassionate Use Program that allows subscribers to use cannabis products for medicinal purposes. This programme was created in 2015 and is caters to patients of medical conditions such as epilepsy, seizures, terminal cancer, multiple sclerosis, incurable neurological disorders, autism and ALS.
Now, with the advancements in the way marijuana is covering ground, cannabis advocates in Texas are pressuring legislators to expand the program. There are expectations that the expansion will include patients suffering from PTSD.
Ruark believes that people are largely unaware of the medicinal programme in Texas. Also, he believes these gummies will change this. He thinks that his company can raise awareness about the state’s medical marijuana program.
Increasing The Cannabis Family by 2 Million
Increased reach will allow two million patients to use it who qualify for it even now but don’t use it because they don’t know about the program.
The president of the dispensaries wants everyone to benefit from the nature’s gift. He wants everyone to reap the benefits of cannabis. It may be of special benefit for veterans in dealing with PTSD after their return back to a normal life.
These lovely gummy treats come in a bottle that costs $60 and contains 200 milligrams of THC in total.
Cannabis Antibiotics Can Be Solution For Treating Drug-Resistant Diseases
The cannabis plant contains multiple components of varying benefits, of which some constituents are psychoactive while others are non-psychoactive and have other pharmacological impacts. Because of the pharmacological benefits, researchers are working to formulate cannabis antibiotics.
According to the research of The University of Queensland, CBD is a component present in marijuana, is non-psychoactive, and is capable of killing bacteria. It is useable in antibiotics due to its ability to kill bacteria responsible for gonorrhea, meningitis, and legionnaires.
Moreover, according to studies, there is a possibility that drug-resistance diseases can cause more than 10 million deaths per year by 2050. The UN warns that there is an urgent need to deal with drug-resistant illnesses. Furthermore, finding solutions to the problems of drug resistance must be of utmost priority.
Drug resistance is growing, leading to critical problems shortly. According to neurologists, within five years, the NHS will successfully develop effective cannabis-antibiotics. Moreover, the treatment of drug-resistant diseases will be possible with the use of this marijuana containing antibiotics.
Cannabis In Antibiotics
CBD is the cannabidiol, a major non-psychoactive and second-most prevalent component of the active ingredients of marijuana. Two institutions researched using cannabis in antibiotics. The institutions that collaborate for research are the University of Queensland and Botanix Pharmaceuticals Limited.
In their research, researchers examined how the CBD of cannabis penetrates through the protective membranes of multiple bacteria. Moreover, not only does the CBD enter the bacteria, but it also kills them.
Of the bacteria through which CBD penetrates are bacteria for meningitis, legionella, and Neisseria gonorrhea. The legionella bacteria cause legionnaire’s disease characterized by cough, shortness of breath, high fever, muscle pain, nausea, vomiting, and headache.
The researchers found that CBD was able to break down the biofilm of the bacteria. Biofilm is a slimy build-up of bacteria released by it to survive against antibiotic treatment. Moreover, the biofilm’s slimy layer is similar to a dental plaque on the surface.
What Is In The Future For Cannabis?
Cannabis-infused antibiotics may be available in the market. According to Professor Mike Barnes, pretty-soon general practitioners will start prescribing CBD pills to treat infectious diseases. Research on marijuana is progressing fast. Moreover, there are chances of formulating much better cannabis products for medicinal use.
According to Mike Barnes, it is high time that individuals understand the medical benefits of marijuana and take advantage of the plant to its full capacity. Moreover, the marijuana plant is useable in various ways to improve the condition of patients.
The new research led by the University of Queensland and Botanix Pharmaceutical Limited is helpful in the subject. However, further research is vital for developing much better, safer, and effective drugs containing CBD of marijuana.
More Studies Essential For A Better Future
According to Professor Mike Barnes, if CBD is placed next to bacteria in a plate, the cannabidiol will kill the bacteria right away. However, if a tablet containing CBD is on the same plate as the bacteria, the effect of CBD will be slower.
The professor is confident that with further research on the subject, better medicine formulation can occur for treating drug-resistant diseases. Moreover, UK regulators can formulate something that can fight against antibiotic-resistant gonorrhea. Furthermore, the formation of antibiotics for drug-resistant gonorrhea is the utmost priority of the World Health Organization.
Once the formulation of the cannabis-containing antibiotics is complete, the drugs will need the approval to conduct preclinical-trials and clinical trials. After completing the clinical trials and research investigations, the authorities will consider the drugs for approval after which they will be available in the market.
Deep studies and research investigations enable the formulation of a more effective formulation. The quicker the cannabis containing antibiotics gets approval, the sooner they will be in the market for treating drug-resistant bacterial diseases.
Cannabis2 years ago
How CBD oil works?
Cannabis2 years ago
Research Suggests Cannabis Effective in Treating Endometriosis
Health1 year ago
Diabetes Freedom Review – A Natural Way To Beat Diabetes Type 2
Cannabis2 years ago
CBD Gummies: How does it work? Benefits, Pricing and Packages
Featured2 years ago
Prosper Wellness TurmeriCBD Review – A combination of Turmeric and CBD?
Cannabis2 years ago
What are the main advantages of consuming CBD oil?
Health1 year ago
VitaMove, a Popular Formula to Relieve Back Pain is Restocked
Cannabis1 year ago
Can Cannabis Survive in Pharma?